<DOC>
	<DOCNO>NCT00807053</DOCNO>
	<brief_summary>The primary objective study demonstrate efficacy ciclesonide HFA , apply nasal aerosol daily , patient SAR . The secondary objective evaluate Quality-of-Life safety .</brief_summary>
	<brief_title>Dose-ranging Study Assess Efficacy Safety Ciclesonide HFA Nasal Aerosol Adult Adolescent Patients 12 Years Older With Seasonal Allergic Rhinitis ( SAR ) ( BY9010/M1-602 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>1 . Male female 12 year old 2 . General good health , free concomitant condition treatment could interfere study conduct , influence interpretation study observations/results , put patient increase risk trial 3 . A history SAR relevant seasonal allergen minimum two year immediately precede study season . The SAR must sufficient severity require treatment ( continuous intermittent ) past investigator´s judgment expect require treatment throughout entire study period 4 . A demonstrated sensitivity grass tree pollen know induce SAR standard skin prick test . A positive test define wheal diameter least 3 mm large control wheal skin prick test . Documentation positive result 12 month prior screen acceptable 5 . Female childbearing potential currently take continue use medically reliable method contraception entire study duration ( e.g . oral , injectable , transcutaneous implantable contraceptive intrauterine device doublebarrier protection ) . Women childbearing potential , less 1 year postmenopausal , require negative pregnancy test Screnning Visit ( B0 ) well last ontreatment ( T2 ) 6 . Capable understanding requirement , risk benefit study participation , , judge investigator , capable give informed consent compliance study requirement ( visit , recordkeeping , etc . ) 1 . Pregnancy , nursing plan become pregnant donate gamete ( sperm ) vitro fertilization study period 30 day follow study period . 2 . History physical finding nasal pathology , include nasal polyp ( within last 60 day ) clinically significant respiratory tract malformation , recent nasal biopsy ( within last 60 day ) , nasal trauma , surgery atrophic rhinitis rhinitis medicamentosa ( within last 60 day ) 3 . Participation investigational drug trial within 30 day precede Screening Visit ( B0 ) 4 . A known hypersensitivity corticosteroid excipients formulation 5 . History respiratory infection disorder ( include , limited bronchitis , pneumonia , common cold , acute chronic sinusitis , flu , severe acute respiratory syndrome ( SARS ) ) within 14 day precede Screening Visit ( B0 ) , development respiratory infection Baseline Period . 6 . History alcohol drug abuse within precede two year 7 . History positive test HIV , hepatitis B hepatitis C 8 . Active asthma require treatment inhale systemic corticosteroid and/or routine use ßagonists controller drug ( e.g. , theophylline , leukotriene antagonist , etc . ; intermittent use ( less equal 3 us per week ) inhale short act ßagonists acceptable 9 . Plans travel outside study area ( know pollen area investigative site ) two consecutive day OR 5 day total start 7 day prior Randomization Visit ( T0 ) final Treatment Visit ( T2 ) 10 . Use prohibit concomitant medication within prescribe ( per protocol ) time since last dose period prior Screening Visit ( B0 ) entire treatment duration . 11 . Use antibiotic therapy acute condition within 14 day prior Screening Visit ( B0 ) . Low dos antibiotic take prophylaxis permitted therapy start prior Screening Visit ( B0 ) AND expect continue throughout trial . 12 . Initiation immunotherapy study period dose escalation study period . However , initiation immunotherapy 90 day prior Screening Visit ( B0 ) AND use stable ( maintenance ) dose ( 30 day ) may consider inclusion . 13 . Previous participation intranasal ciclesonide HFA nasal aerosol study . 14 . Nonvaccinated exposure active infection , chickenpox measles within 21 day precede Screening Visit ( B0 ) . 15 . Use topical corticosteroid concentration excess 1 % hydrocortisone equivalent within 30 day prior Screening Visit ( B0 ) ; use topical hydrocortisone equivalent concentration cover great 20 % body surface ; presence underlying condition ( judged investigator ) reasonably expect require treatment preparation course study . 16 . Initiation pimecrolimus cream 1 % great tacrolimus ointment 0.03 % great study period plan dose escalation study period . However , initiation creams/ointments 30 day prior Screening Visit ( B0 ) AND use stable ( maintenance ) dose study period may consider inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Seasonal Allergic Rhinitis</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>SAR</keyword>
</DOC>